US 9,808,501 B2
Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
Jack J. Hawiger, Nashville, TN (US); Ruth Ann Veach, Brentwood, TN (US); Jozef Zienkiewicz, Nashville, TN (US); Yan Liu, Nashville, TN (US); Robert D. Collins, Nashville, TN (US); and Amy S. Major, Brentwood, TN (US)
Assigned to Vanderbilt University, Nashville, TN (US)
Filed by VANDERBILT UNIVERSITY, Nashville, TN (US)
Filed on Jun. 20, 2016, as Appl. No. 15/187,207.
Application 15/187,207 is a continuation of application No. 14/705,121, filed on May 16, 2015, granted, now 9,370,549.
Application 14/705,121 is a continuation of application No. 14/349,918, granted, now 9,044,433, issued on Jun. 2, 2015, previously published as PCT/US2012/058982, filed on Oct. 5, 2012.
Claims priority of provisional application 61/544,105, filed on Oct. 6, 2011.
Prior Publication US 2017/0042964 A1, Feb. 16, 2017
Int. Cl. A61K 38/16 (2006.01); A61K 38/12 (2006.01); A61K 38/08 (2006.01); A61K 31/397 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/16 (2013.01) [A61K 31/397 (2013.01); A61K 38/08 (2013.01); A61K 38/12 (2013.01); A61K 45/06 (2013.01)] 27 Claims
 
1. An isolated peptide consisting of the amino acid sequence set forth in SEQ ID NO: 10 and a solubility tag consisting of 5 to 7 hydrophilic amino acids.